190 related articles for article (PubMed ID: 16888216)
1. NAP, a peptide derived from the activity-dependent neuroprotective protein, modulates macrophage function.
Quintana FJ; Zaltzman R; Fernandez-Montesinos R; Herrera JL; Gozes I; Cohen IR; Pozo D
Ann N Y Acad Sci; 2006 Jul; 1070():500-6. PubMed ID: 16888216
[TBL] [Abstract][Full Text] [Related]
2. Activity-dependent neuroprotective protein: from gene to drug candidate.
Gozes I
Pharmacol Ther; 2007 May; 114(2):146-54. PubMed ID: 17363064
[TBL] [Abstract][Full Text] [Related]
3. The influence of the peptide NAP on Mac-1-deficient mice following closed head injury.
Zaltzman R; Alexandrovich A; Trembovler V; Shohami E; Gozes I
Peptides; 2005 Aug; 26(8):1520-7. PubMed ID: 16042992
[TBL] [Abstract][Full Text] [Related]
4. Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model.
Vulih-Shultzman I; Pinhasov A; Mandel S; Grigoriadis N; Touloumi O; Pittel Z; Gozes I
J Pharmacol Exp Ther; 2007 Nov; 323(2):438-49. PubMed ID: 17720885
[TBL] [Abstract][Full Text] [Related]
5. NAP protects hippocampal neurons against multiple toxins.
Zemlyak I; Manley N; Sapolsky R; Gozes I
Peptides; 2007 Oct; 28(10):2004-8. PubMed ID: 17869381
[TBL] [Abstract][Full Text] [Related]
6. Neuroprotective effects of NAP against excitotoxic brain damage in the newborn mice: implications for cerebral palsy.
Sokolowska P; Passemard S; Mok A; Schwendimann L; Gozes I; Gressens P
Neuroscience; 2011 Jan; 173():156-68. PubMed ID: 21073926
[TBL] [Abstract][Full Text] [Related]
7. The expression of activity-dependent neuroprotective protein (ADNP) is regulated by brain damage and treatment of mice with the ADNP derived peptide, NAP, reduces the severity of traumatic head injury.
Gozes I; Zaltzman R; Hauser J; Brenneman DE; Shohami E; Hill JM
Curr Alzheimer Res; 2005 Apr; 2(2):149-53. PubMed ID: 15974912
[TBL] [Abstract][Full Text] [Related]
8. Protection against tauopathy by the drug candidates NAP (davunetide) and D-SAL: biochemical, cellular and behavioral aspects.
Shiryaev N; Pikman R; Giladi E; Gozes I
Curr Pharm Des; 2011; 17(25):2603-12. PubMed ID: 21728979
[TBL] [Abstract][Full Text] [Related]
9. From vasoactive intestinal peptide (VIP) through activity-dependent neuroprotective protein (ADNP) to NAP: a view of neuroprotection and cell division.
Gozes I; Divinsky I; Pilzer I; Fridkin M; Brenneman DE; Spier AD
J Mol Neurosci; 2003; 20(3):315-22. PubMed ID: 14501014
[TBL] [Abstract][Full Text] [Related]
10. NAP protects against cytochrome c release: inhibition of the initiation of apoptosis.
Zemlyak I; Sapolsky R; Gozes I
Eur J Pharmacol; 2009 Sep; 618(1-3):9-14. PubMed ID: 19619522
[TBL] [Abstract][Full Text] [Related]
11. Microtubules, schizophrenia and cognitive behavior: preclinical development of davunetide (NAP) as a peptide-drug candidate.
Gozes I
Peptides; 2011 Feb; 32(2):428-31. PubMed ID: 21050875
[TBL] [Abstract][Full Text] [Related]
12. A peptide derived from activity-dependent neuroprotective protein (ADNP) ameliorates injury response in closed head injury in mice.
Beni-Adani L; Gozes I; Cohen Y; Assaf Y; Steingart RA; Brenneman DE; Eizenberg O; Trembolver V; Shohami E
J Pharmacol Exp Ther; 2001 Jan; 296(1):57-63. PubMed ID: 11123362
[TBL] [Abstract][Full Text] [Related]
13. Recombinant activity-dependent neuroprotective protein protects cells against oxidative stress.
Steingart RA; Gozes I
Mol Cell Endocrinol; 2006 Jun; 252(1-2):148-53. PubMed ID: 16704895
[TBL] [Abstract][Full Text] [Related]
14. Peptide antagonists of ethanol inhibition of l1-mediated cell-cell adhesion.
Wilkemeyer MF; Menkari CE; Spong CY; Charness ME
J Pharmacol Exp Ther; 2002 Oct; 303(1):110-6. PubMed ID: 12235240
[TBL] [Abstract][Full Text] [Related]
15. A novel VIP responsive gene. Activity dependent neuroprotective protein.
Gozes I; Zamostiano R; Pinhasov A; Bassan M; Giladi E; Steingart RA; Brenneman DE
Ann N Y Acad Sci; 2000; 921():115-8. PubMed ID: 11193814
[TBL] [Abstract][Full Text] [Related]
16. Risperidone and NAP protect cognition and normalize gene expression in a schizophrenia mouse model.
Vaisburd S; Shemer Z; Yeheskel A; Giladi E; Gozes I
Sci Rep; 2015 Nov; 5():16300. PubMed ID: 26553741
[TBL] [Abstract][Full Text] [Related]
17. NAP (davunetide) enhances cognitive behavior in the STOP heterozygous mouse--a microtubule-deficient model of schizophrenia.
Merenlender-Wagner A; Pikman R; Giladi E; Andrieux A; Gozes I
Peptides; 2010 Jul; 31(7):1368-73. PubMed ID: 20417241
[TBL] [Abstract][Full Text] [Related]
18. Novel tubulin and tau neuroprotective fragments sharing structural similarities with the drug candidate NAP (Davuentide).
Gozes I; Iram T; Maryanovsky E; Arviv C; Rozenberg L; Schirer Y; Giladi E; Furman-Assaf S
J Alzheimers Dis; 2014; 40 Suppl 1():S23-36. PubMed ID: 24503616
[TBL] [Abstract][Full Text] [Related]
19. Activity-dependent neuroprotective protein (ADNP) differentially interacts with chromatin to regulate genes essential for embryogenesis.
Mandel S; Rechavi G; Gozes I
Dev Biol; 2007 Mar; 303(2):814-24. PubMed ID: 17222401
[TBL] [Abstract][Full Text] [Related]
20. Expression of activity-dependent neuroprotective protein in the immune system: possible functions and relevance to multiple sclerosis.
Braitch M; Kawabe K; Nyirenda M; Gilles LJ; Robins RA; Gran B; Murphy S; Showe L; Constantinescu CS
Neuroimmunomodulation; 2010; 17(2):120-5. PubMed ID: 19923857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
